Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for LH Pulse Frequency in Pubertal Girls with Hyperandrogenism
NCT04723862Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Nov 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperandrogenism comparing Spironolactone with Placebo (2 arms). Primary endpoint: Change in Sleep-Associated Luteinizing Hormone (LH) Pulse Frequency at 2 months. Started Nov 2021; status: recruiting.
02
Drugs
spironolactone
03
Conditions
hyperandrogenism
Beyond the preview
Go deeper on NCT04723862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723862.